Early Detection and Immediate Care for Pancreatic Cancer
According to the Pancreatic Cancer Action Network, pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States around 2020. Penn Medicine’s Pancreatic Cancer Research Center (PCRC), is answering this urgent need to establish new therapies for pancreatic cancer.
The PCRC has four areas of focus:
- Clinical Trials: To have every pancreatic cancer patient no matter what stage enrolled in a pancreatic clinical trial
- Early Detection: Developing early detection methods for pancreatic cancer
- Novel Therapies: Testing new drugs in the lab and quickly deploying the findings to patients
- Personalized Treatment: Providing each patient with a personalized treatment plan
Learn more about the Pancreatic Cancer Research Center on the School of Medicine website.
Multidisciplinary Approach to Pancreatic Cancer
Penn’s PCRC multidisciplinary team of medical oncologists, translational scientists, surgeons, gastroenterologists, radiation oncologists, pathologists and support services work collaboratively to bring discoveries from the lab to the patient’s bedside.
Since our team works together each and every day, our patients receive personalized treatment plans, as well as access to the latest therapies and clinical trials.
Why Penn’s Pancreatic Cancer Research Center Program is Different
- We are pioneers of leading edge, translational research that combines basic science research and clinical investigation.
- We offer the latest clinical trials that are available for all stages of pancreatic cancer.
- We take a multidisciplinary approach — integrating medical oncology, surgery, gastroenterology, radiation oncology, and pathology — to deliver comprehensive and personalized options to our patients.
Schedule an Appointment
If you have been diagnosed with pancreatic cancer or are seeking information on one of our many pancreatic clinical trials here at Penn, please contact: Patricia Gambino, MSN, RN, Pancreatic Cancer Nurse Navigator via email at Patricia.Gambino@uphs.upenn.edu or phone at 215-615-0537.
Learn more about Penn’s Oncology Navigators and support services.
Penn’s Pancreatic Cancer Clinical Trials
Penn’s Pancreatic Cancer Clinical Trials Penn Medicine has many pancreatic clinical trials, for every stage of pancreatic cancer. To view them, visit the PCRC School of Medicine website, or contact your Penn oncologist or Patricia Gambino, MSN, RN.
Meet the Team
Ben Z. Stanger, MD, PhD, Director, PCRC
Dr. Stanger is an Associate Professor of Medicine and Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania, and an Associate Investigator of the Abramson Family Cancer Research Institute. He is an elected member of the American Society of Clinical Investigation and a former Pew Scholar in the Biomedical Sciences.
Robert H. Vonderheide, MD, DPhil, Director, Abramson Cancer Center
Dr. Vonderheide, MD, DPhil, is the Director of the Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania and the John H. Glick, MD Abramson Cancer Center’s Director Professor. Dr. Vonderheide graduated from Oxford University as a Rhodes Scholar, and Harvard Medical School. He completed training in internal medicine and medical oncology at the Massachusetts General Hospital and the Dana Farber Cancer Institute.
Dr. Vonderheide is a distinguished scientist and clinician who has deciphered mechanisms of cancer immune surveillance and developed novel cancer therapeutics, particularly in pancreatic cancer. He is well-recognized for driving the development of agonist CD40 antibodies, now in later stage clinical trials as potential immune therapy of cancer. Dr. Vonderheide discovered telomerase as a universal tumor antigen and has led the efforts to develop telomerase vaccination for both therapy and the prevention of cancer in healthy individuals. He has helped lead a team to show that stereotactic radiation therapy in combination with dual checkpoint blockade represents a synergistic path for immune activation in cancer. Dr. Vonderheide merges his clinical investigations with rigorous studies in mouse models or other laboratory systems. Dr. Vonderheide has been continuously funded by the NCI, and his high-impact findings have been published in Nature, Science, Cell and the New England Journal of Medicine.
Ursina Teitelbaum, MD,
Clinical Director, PCRC
Dr. Teitelbaum is an Associate Professor of Clinical Medicine at Penn Medicine and serves as Clinical Director of Penn’s PCRC. She is also a dedicated GI medical oncologist with special interest in treating pancreas adenocarcinoma, and she serves as Leader of the Pancreas Cancer Service Line at the Abramson Cancer Center. She was recently elected to the Penn Medicine Academy of Master Clinicians, which honors Penn Medicine clinicians that exemplify the highest standards of clinical excellence, humanism and professionalism.
Ways to Give
Every dollar helps fund our pancreatic clinical and translational efforts, and accelerates innovation. Give here
For more information about giving opportunities, please contact Andrew Bellet, Associate Director of Development, via email at email@example.com or phone at 215-573-0548.